Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) - Share price, News & Analysis

CRBP fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

CRBP Stock Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.

Rewards

Revenue is forecast to grow 79.12% per year

Risk Analysis

Makes less than USD$1m in revenue ($97K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Does not have a meaningful market cap ($28M)

Corbus Pharmaceuticals Holdings Competitors

Enzon Pharmaceuticals

OTCPK:ENZN

US$25.1m

AIkido Pharma

NasdaqCM:AIKI

US$32.4m

Applied Genetic Technologies

NasdaqGM:AGTC

US$28.5m

Nuo Therapeutics

OTCPK:AURX

US$51.4m

Price History & Performance

Summary of all time highs, changes and price drops for Corbus Pharmaceuticals Holdings
Historical stock prices
Current Share Price	US$0.22
52 Week High	US$1.32
52 Week Low	US$0.21
Beta	1.93
1 Month Change	-21.45%
3 Month Change	-35.04%
1 Year Change	-80.40%
3 Year Change	-96.05%
5 Year Change	-96.64%
Change since IPO	-92.62%

Recent News & Updates

Aug 09

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

Shareholder Returns

	CRBP	US Biotechs	US Market
7D	-16.2%	-2.0%	1.1%
1Y	-80.4%	-23.0%	-9.0%

Return vs Industry: CRBP underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: CRBP underperformed the US Market which returned -9% over the past year.

Price Volatility

Is CRBP's price volatile compared to industry and market?
CRBP volatility
CRBP Average Weekly Movement	12.7%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.6%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CRBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CRBP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2009	41	Yuval Cohen	https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.

Corbus Pharmaceuticals Holdings Fundamentals Summary

How do Corbus Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
CRBP fundamental statistics
Market Cap	US$27.75m
Earnings (TTM)	-US$35.12m
Revenue (TTM)	US$97.32k

287.7x

P/S Ratio

-0.8x

P/E Ratio

Is CRBP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRBP income statement (TTM)
Revenue	US$97.32k
Cost of Revenue	US$20.25m
Gross Profit	-US$20.15m
Other Expenses	US$14.98m
Earnings	-US$35.12m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.28
Gross Margin	-20,701.99%
Net Profit Margin	-36,089.12%
Debt/Equity Ratio	38.8%

How did CRBP perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is CRBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRBP?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CRBP. This is calculated by dividing CRBP's market cap by their current preferred multiple.
What is CRBP's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$27.75m

CRBP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CRBP's PB Ratio compare to its peers?

CRBP PB Ratio vs Peers

The above table shows the PB ratio for CRBP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	5.8x
ENZN Enzon Pharmaceuticals	7.6x	n/a	US$25.1m
AIKI AIkido Pharma	0.4x	-10.6%	US$32.4m
AGTC Applied Genetic Technologies	0.6x	6.0%	US$28.5m
AURX Nuo Therapeutics	14.4x	n/a	US$51.4m
CRBP Corbus Pharmaceuticals Holdings	0.6x	9.4%	US$27.7m

Price-To-Book vs Peers: CRBP is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (5.8x).

Price to Earnings Ratio vs Industry

How does CRBP's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: CRBP is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.9x)

Price to Book Ratio vs Fair Ratio

What is CRBP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRBP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.6x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRBP's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CRBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRBP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRBP's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Future Growth

How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

9.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRBP's revenue (79.1% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: CRBP's revenue (79.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Corbus Pharmaceuticals Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-10.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CRBP is currently unprofitable.

Growing Profit Margin: CRBP is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CRBP is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).

Return on Equity

High ROE: CRBP has a negative Return on Equity (-71%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Corbus Pharmaceuticals Holdings's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CRBP's short term assets ($75.2M) exceed its short term liabilities ($15.6M).

Long Term Liabilities: CRBP's short term assets ($75.2M) exceed its long term liabilities ($17.0M).

Debt to Equity History and Analysis

Debt Level: CRBP has more cash than its total debt.

Reducing Debt: CRBP's debt to equity ratio has increased from 0.1% to 38.8% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRBP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CRBP has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 25% each year.

Discover healthy companies

Dividend

What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRBP's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRBP has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure

CEO

Yuval Cohen (47 yo)

8.33yrs

Tenure

US$4,843,519

Compensation

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...

CEO Compensation Analysis

Compensation vs Market: Yuval's total compensation ($USD4.84M) is above average for companies of similar size in the US market ($USD758.99K).

Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: CRBP's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Experienced Board: CRBP's board of directors are considered experienced (5.7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: CRBP insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/08/18 00:00
End of Day Share Price	2022/08/18 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31